Onward Medical has secured a $1.1m grant from the Christopher & Dana Reeve Foundation to support an ongoing study of its Onward ARC-BCI System. Credit: ArmadilloPhotograp via Shutterstock.

Onward Medical has won a $1.1m grant from the Christopher & Dana Reeve Foundation to support an ongoing study of its Onward ARC-BCI System to restore thought-driven movement of the hands and arms after spinal cord injury (SCI).

The grant is set to support an additional four participants to be implanted with the brain-computer interface (BCI) system. The early feasibility study evaluates the use of BCI to restore the thought-driven use of the hands and arms after SCI. The first participant in the study received their investigational ARC-BCI implant in August 2023.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The ARC-BCI platform pairs Onward’s ARC-IM system with BCI technology from CEA-Clinatec, which registers brain intention to move upper extremities and decodes signals using AI. The ARC-IM stimulator then captures the decoded information to precisely stimulate the spinal cord.

Onward has already shared data showing that the combination has demonstrated positive results in providing movement for the paralysed lower legs. The company won US Food and Drug Administration (FDA) breakthrough device designation for the technology in February 2024, then shortly after was accepted into the FDA’s new Total Product Lifecycle Advisory Program (TAP).

BCI’s are chips implanted in brain tissue that take brain signals and translate them into commands. The measured signals, which can be described as ‘thoughts’, are relayed to a secondary, external device which then carries out a specific function. The tech has received significant attention due to Elon Musk’s company Neuralink, which has now implanted two paralysed patients with its device, Telepathy. 

See Also:

Other companies, including Brown University spinout BrainGate, are also making movements in the space. The company reported a successful case study last month, highlighting that its technology translates brain signals into speech with an accuracy of up to 97%, meaning patients with speech impairments could benefit from the implant.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, all eyes are on Onward as it aims to commercialise its non-invasive ARC-EX therapy in the US, following an April 2024 FDA De Novo application submission. This submission is supported by positive data from the Up-LIFT study (NCT04697472).

Onward Medical’s CEO Dave Marver said: “While other companies are using BCI technology to interface with computers, Onward is leading the pursuit of BCI-augmented movement restoration. We are grateful to the Christopher & Dana Reeve Foundation for its support, which enables us to expand this important study.”